|
|
Organogenesis Holdings Inc (ORGO) |
|
Price: $3.0200
$0.03 
1.003%
|
| Day's High:
| $3.055
| Week Perf:
| 5.59 %
|
| Day's Low: |
$ 2.97 |
30 Day Perf: |
17.97 % |
| Volume (M): |
308 |
52 Wk High: |
$ 4.71 |
| Volume (M$): |
$ 931 |
52 Wk Avg: |
$2.92 |
| Open: |
$2.97 |
52 Wk Low: |
$1.96 |
|
|
| Market Capitalization (Millions $) |
403 |
| Shares
Outstanding (Millions) |
133 |
| Employees |
862 |
| Revenues (TTM) (Millions $) |
448 |
| Net Income (TTM) (Millions $) |
12 |
| Cash Flow (TTM) (Millions $) |
-9 |
| Capital Exp. (TTM) (Millions $) |
32 |
Organogenesis Holdings Inc
Organogenesis Holdings Inc is a globally recognized healthcare company that operates in the regenerative medicine and biomaterials industries. The company was founded in 1985 and is headquartered in Canton, Massachusetts. Organogenesis is committed to providing innovative solutions for wound healing, tissue regeneration, and surgical products that enhance the standard of care for patients globally.
Organogenesis Holdings focuses on developing products that are biologically-based and offer regenerative properties to promote healing and restoration of damaged tissues. The products developed by the company are based on advanced scientific research that integrates biological and physical factors to create a unique bioengineering product. The three main areas of focus for Organogenesis are Advanced Wound Care, Surgical & Sports Medicine, and Orthobiologics.
Advanced Wound Care is the primary focus of the company, and it offers an extensive product line to aid in the process of wound healing. The products developed for Advanced Wound Care include Apligraf, a bioengineered living cell product that aids in the healing of diabetic foot ulcers, venous leg ulcers, and pressure sores, and Dermagraft, a bioengineered dermal substitute that offers the ability to restore tissue for the treatment of chronic wounds.
Organogenesis Holdings aims to provide innovative surgical and sports medicine solutions for tissue repair, restoration, and healing. The company's products in this category include NuShield, a xenogenic tissue matrix that provides a barrier to soft tissue, and Allosync, a product that aids in the re-building of damaged cartilage.
Orthobiologics is a focus area of Organogenesis, and the company offers products that provide support and restoration for bone tissue. The products in this category include Gintuit, a product that is used for tissue regeneration and restoration, and NuCel, which is used for bone grafting and repair.
Organogenesis also places a great deal of focus on research and development to ensure that it remains at the forefront of the regenerative medicine industry. The company's R&D team is responsible for exploring new technologies and techniques that can be used to develop new products that offer better results to patients.
In conclusion, Organogenesis Holdings Inc is a leading healthcare company that is committed to research, development, and innovation in the regenerative medicine and biomaterials industries to ensure that it provides optimal solutions for tissue restoration and healing for patients globally.
Company Address: 85 Dan Road Canton 2021 MA
Company Phone Number: 575-0775 Stock Exchange / Ticker: NASDAQ ORGO
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Clinical Study
Published Tue, Oct 1 2024 8:05 PM UTC
Diabetic foot ulcers (DFUs) pose a significant challenge to healthcare systems around the globe, affecting thousands of patients annually and often leading to increased morbidity, amputations, and healthcare costs. In a recent publication in the 'Journal of Wound Care', Organogenesis Holdings Inc. reported compelling results from a randomized controlled trial that evaluated ...
|
| Clinical Study
Published Thu, Aug 8 2024 8:04 PM UTC
'CANTON, Mass., Aug. 8, 2024 - Organogenesis Holdings Inc. (Nasdaq: ORGO), a frontrunner in regenerative medicine dedicated to the advanced wound care and surgical sports medicine markets, has announced a significant development update on its ReNu? program. ReNu?, a cryopreserved amniotic suspension allograft (ASA), is designed to manage the symptoms associated with knee ost...
|
| Clinical Study
Published Thu, May 2 2024 11:00 AM UTC
Organogenesis Holdings Inc., a prominent regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine solutions, recently announced the successful accomplishment of its Phase 3 clinical trial for ReNu. This randomized control trial evaluated the safety and efficacy of ReNu, a cryopreserved amniotic suspension allograft (ASA), in managing...
|
| Organogenesis Holdings Inc
Organogenesis Holdings Inc has experienced significant stock gains in recent months. However, a closer look at its financial results for the third quarter of the 2023 earnings season reveals a mixed picture. While income per share remained stable, profit and revenue experienced substantial declines. This article aims to interpret the impact of these financial results on Organogenesis Holdings Inc going forward.
1. Stock Gain:
Over the last five trading days, the stock of Organogenesis Holdings Inc has gained an impressive 16.1%. Furthermore, the stock has surged by a staggering 44.23% over the past 90 days. Currently trading on NASDAQ, the stock is performing exceptionally well, trading 34% above its 52-week average. These gains indicate investor confidence in the company's future prospects.
|
| Organogenesis Holdings Inc
Organogenesis Holdings Inc., a leading company in the Major Pharmaceutical Preparations sector, recently reported its financial results for the April to June 30, 2023 span. The earnings per share (EPS) for this period saw a significant decline of -42.86%, dropping to $0.04 per share compared to $0.07 per share in the same period the previous year. However, it is worth noting that the EPS turned positive from -$0.02 per share in the prior reporting season.
The revenue for Organogenesis Holdings Inc. also experienced a decrease of -3.365%, falling to $117.32 million from $121.40 million in the same reporting season a year prior. On a sequential basis, the revenue showed growth, advancing by 8.987% from $107.64 million. This decline in revenue is in contrast to the overall trend in the Major Pharmaceutical Preparations sector, which posted a 2.65% rise in top-line relative to the second quarter of 2022 in the second quarter of 2023.
|
| Per Share |
Current |
| Earnings (TTM) |
0.09 $ |
| Revenues (TTM) |
3.36 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.74 $
|
| Book Value |
2.08 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
0.09 $
|
| Revenues (TTM) |
3.36 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.74 $
|
| Book Value |
2.08 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
On February 29 2024 the Organogenesis Holdings Inc provided following guidance
Organogenesis Holdings Inc., a prominent company specializing in regenerative medicine, released its financial results for the fourth quarter of 2023 and fiscal year 2023 on February 29, 2024. As a company dedicated to developing, producing, and distributing product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, Organogenesis Holdings Inc. has seen significant growth and success in these areas.
For the fourth quarter of 2023, Organogenesis Holdings Inc. reported strong financial performance, with revenue increasing substantially compared to the previous quarter. This growth can be attributed to the successful commercialization of new product solutions and increased dem...
|
|
|
